MAPK8 and cancer: By using mutant c-Jun defective for phosphorylation, and chemical inhibitor SP600125, we also demonstrated an essential role of JNK-mediated phosphorylation of c-Jun in controlling PES1 expression, suggesting that suppression the expression of PES1 by blockade of JNK activity could be of therapeutic potential for cancer treatment.